CINCINNATI– CinRx Pharma, a mosaic of biotechnology companies accelerating transformational new medicines to patients, announced today that Gavin Samuels, M.D., M.B.A has assumed the role of Chief Business Officer. In his new role, Gavin will be responsible for leading corporate, strategic and business development and transactions for the CinRx portfolio.
“CinRx’s bold and important mission to overcome historic drug development hurdles and improve the drug development process is only possible through our dedicated and highly-experienced team, including Gavin,” said Jon Isaacsohn, M.D., FACC, Chief Executive Officer of CinRx Pharma. “Gavin’s strategic input and expertise has been instrumental in our success to date, and it’s my pleasure to announce him officially joining our C-suite where he can further extend his leadership and guide the next generation of CinRx.”
“Leadership to me is inspiring a team to reach their full potential through drive, passion and clear, audacious goals. The CinRx leadership team is completely aligned with this philosophy,” said Gavin. “I’m confident that alongside our experienced team of life science leaders, we will realize our mission of accelerating high-potential medicines as quickly and efficiently as possible from the lab to patients in need.”
Gavin joins CinRx with 25 years of experience across large pharma and emerging biotech settings in various functions including business development, private and public financing, investor relations, and strategy. As a former physician, his focus and passion are developing high potential medicines and care for patients in need. Before joining CinRx, he served as Global Head of Strategy & Growth Initiatives at Lonza Biologics, where he oversaw strategic development and implementation of new business models and strategies. Prior to this, Gavin held transactional, corporate venture and business development positions at Merck, Pfizer and Teva Pharmaceuticals. (IANS)
